中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2015年
22期
2688-2691
,共4页
肿瘤%化学疗法, 辅助%胃肠道%雷贝拉唑%奥美拉唑%托烷司琼%地塞米松%治疗结果
腫瘤%化學療法, 輔助%胃腸道%雷貝拉唑%奧美拉唑%託烷司瓊%地塞米鬆%治療結果
종류%화학요법, 보조%위장도%뢰패랍서%오미랍서%탁완사경%지새미송%치료결과
Neoplasms%Chemotherapy,adjuvant%Gastrointestinal tract%Rabeprazole%Omeprazole%Tropisetron%Dexamethasone%Treatment outcome
目的：探讨雷贝拉唑联合托烷司琼及地塞米松防治肿瘤患者化疗所致消化道反应的疗效。方法选取2014年2—7月，在中国医学科学院北京协和医学院肿瘤医院门诊化疗的非胃肠道恶性肿瘤患者120例为研究对象。采用随机数字表法将患者分为试验组和对照组各60例，化疗前后及化疗过程中，试验组给予雷贝拉唑+托烷司琼+地塞米松治疗，对照组给予奥美拉唑+托烷司琼+地塞米松治疗，化疗两个周期后（每个周期为21 d）比较两组患者的疗效。结果试验组在抑制恶心、呕吐、反酸及改善食欲、生活质量的疗效上均优于对照组，差异有统计学意义（u值分别为-2.199、-2.178、-2.089、-2.283、-2.062， P＜0.05）；且在临床总疗效上亦优于对照组，差异有统计学意义（ u＝2.137， P＜0.05）。结论雷贝拉唑联合托烷司琼及地塞米松防治化疗药物所致胃肠道反应疗效较好，可作为新一代强效止吐方案，值得临床关注及应用。
目的：探討雷貝拉唑聯閤託烷司瓊及地塞米鬆防治腫瘤患者化療所緻消化道反應的療效。方法選取2014年2—7月，在中國醫學科學院北京協和醫學院腫瘤醫院門診化療的非胃腸道噁性腫瘤患者120例為研究對象。採用隨機數字錶法將患者分為試驗組和對照組各60例，化療前後及化療過程中，試驗組給予雷貝拉唑+託烷司瓊+地塞米鬆治療，對照組給予奧美拉唑+託烷司瓊+地塞米鬆治療，化療兩箇週期後（每箇週期為21 d）比較兩組患者的療效。結果試驗組在抑製噁心、嘔吐、反痠及改善食欲、生活質量的療效上均優于對照組，差異有統計學意義（u值分彆為-2.199、-2.178、-2.089、-2.283、-2.062， P＜0.05）；且在臨床總療效上亦優于對照組，差異有統計學意義（ u＝2.137， P＜0.05）。結論雷貝拉唑聯閤託烷司瓊及地塞米鬆防治化療藥物所緻胃腸道反應療效較好，可作為新一代彊效止吐方案，值得臨床關註及應用。
목적：탐토뢰패랍서연합탁완사경급지새미송방치종류환자화료소치소화도반응적료효。방법선취2014년2—7월，재중국의학과학원북경협화의학원종류의원문진화료적비위장도악성종류환자120례위연구대상。채용수궤수자표법장환자분위시험조화대조조각60례，화료전후급화료과정중，시험조급여뢰패랍서+탁완사경+지새미송치료，대조조급여오미랍서+탁완사경+지새미송치료，화료량개주기후（매개주기위21 d）비교량조환자적료효。결과시험조재억제악심、구토、반산급개선식욕、생활질량적료효상균우우대조조，차이유통계학의의（u치분별위-2.199、-2.178、-2.089、-2.283、-2.062， P＜0.05）；차재림상총료효상역우우대조조，차이유통계학의의（ u＝2.137， P＜0.05）。결론뢰패랍서연합탁완사경급지새미송방치화료약물소치위장도반응료효교호，가작위신일대강효지토방안，치득림상관주급응용。
Objective To explore the efficacy of rabeprazole combined with tropisetron and dexamethasone in the prevention and treatment of gastrointestinal reaction in cancer patients undergoing chemotherapy .Methods We enrolled 120 patients with non-gastrointestinal malignant tumor who received chemotherapy in the outpatient department of the Tumor Hospital of Peking Union Medical College of Chinese Academy of Medical Sciences from February to July , 2014.The patients were divided into two groups: trial group (n=60) and control group (n=60) .Before, after and amid chemotherapy, the trial group was given rabeprazole+tropisetron+dexamethasone , and the control group was given omeprazole +tropisetron+dexamethasone .After two cycles following chemotherapy (one cycle is 21 days), comparison was made between the two groups in efficacy .Results The trial group was superior than the control group in the efficacy regarding the control of nausea , vomiting and sour regurgitation and the improvement of appetite and quality of life (u=-2.199, -2.178, -2.089, -2.283, -2.062; P<0.05); the trial group was better than the control group in general clinical efficacy (u=2.137, P<0.05) .Gonclusion The application of rabeprazole combined with tropisetron and dexamethasone has good efficacy in the prevention and treatment of gastrointestinal reaction induced by chemotherapy .It can be used as a new effective regimen in controlling vomiting , and it should be attached more importance and put into wider application .
